Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Phase II Study to Determine the Safety and Efficacy of 4-HPRN-(4-Hydroxyphenyl) Retinamide for Treating Oral Intraepithelial Neoplasia

NCT00003223 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT00003223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Phase II Study to Determine the Safety and Efficacy of 4-HPRN-(4-Hydroxyphenyl) Retinamide for Treating Oral Intraepithelial Neoplasia
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 1997
Completion date
March 31, 2000
Enrollment
5 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer